Related Experiment Video

Updated: May 27, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease

Jeroen D C Goos1, Charlotte E Teunissen, Robert Veerhuis

  • 1Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands. j.goos@vumc.nl

Neurobiology of Aging
|November 29, 2011
PubMed

Insights

Alzheimer's disease with cerebral microbleeds shows reduced amyloid beta 42, while vascular dementia patients exhibit distinct amyloid profiles and potential blood-brain barrier dysfunction. These findings suggest different causes for these neurodegenerative conditions.

Area of Science:

  • Neuroscience
  • Neurology
  • Biochemistry

Background:

  • Cerebral microbleeds (MBs) are associated with neurodegenerative diseases like Alzheimer's disease (AD) and vascular dementia (VaD).
  • The role of amyloid-beta (Aβ) peptides, specifically Aβ42 and Aβ40, in the pathogenesis and differential diagnosis of dementia subtypes with MBs requires further elucidation.
  • Blood-brain barrier (BBB) integrity may be compromised in dementia, potentially influencing Aβ dynamics.

Purpose of the Study:

  • To investigate the relationship between cerebral microbleeds (MBs) and amyloid-beta (Aβ) profiles in cerebrospinal fluid (CSF) and plasma.
  • To differentiate the roles of Aβ42 and Aβ40 in Alzheimer's disease (AD) with and without MBs, and in vascular dementia (VaD).
  • To assess blood-brain barrier (BBB) function in relation to dementia subtypes and MBs.

Main Methods:

  • Cross-sectional study comparing AD patients with MBs (n=26), AD patients without MBs (n=26), VaD patients (n=11), and controls (n=22).
  • Measurement of CSF and plasma Aβ42 and Aβ40 levels.
  • Assessment of BBB function using albumin ratios.

Main Results:

  • CSF Aβ42 was significantly lower in AD patients with MBs compared to those without.
  • CSF Aβ40 was selectively decreased in VaD patients.
  • Higher albumin ratios in VaD patients indicated impaired BBB function.
  • MB distribution patterns correlated with specific Aβ profiles, suggesting distinct underlying pathologies (e.g., cerebral amyloid angiopathy).

Conclusions:

  • Amyloid-beta metabolism is differentially implicated in AD with MBs and VaD.
  • MB distribution is linked to distinct amyloid profiles, supporting divergent etiologies in dementia.
  • Aβ42 may be retained in the cerebrovasculature of AD patients with MBs, while VaD patients might exhibit altered amyloid clearance mechanisms.

More Related Videos

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats06:39

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats

Published on: October 17, 2018

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...